Antifibrinolytic Agent Application for Non-Surgical Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-surgical medical treatments often result in unwanted swelling, inflammation, and bruising due to procedures like filler injections, chemical peels, and laser treatments, with existing vasoconstriction agents having rebound effects that exacerbate these issues.
Innovation Solution
Applying an antifibrinolytic agent, such as tranexamic acid, before, during, or after non-surgical treatments to minimize bruising and swelling by limiting fibrinolytic activity, thereby enhancing the treatment outcomes and promoting rapid healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If vasoconstriction agents such as epinephrine are applied to reduce bleeding during injection, then bleeding is reduced, but unwanted rebound effects occur as the drug wears off
Solution Approach 1:
The patent converts the harmful rebound effect of vasoconstriction agents into a benefit by using antifibrinolytic agents that prevent fibrin breakdown without causing vascular constriction. The antifibrinolytic agent tranexamic acid inhibits plasminogen activators to prevent fibrinolytic activity, thereby reducing bleeding and bruising without the rebound effect associated with vasoconstrictors.
Solution Approach 2:
The patent changes the mechanism of action from vasoconstriction to antifibrinolytic activity. Instead of using epinephrine which constricts blood vessels, the patent uses tranexamic acid which prevents fibrin breakdown through inhibition of plasminogen activators, fundamentally changing the physiological parameter being targeted.
2Productivity
If needle and pressure are applied during injection, then treatment is delivered, but slight bleeding occurs
Solution Approach 1:
The patent applies antifibrinolytic agent topically to the treatment area before the injection procedure. This preliminary application prevents fibrin breakdown and reduces bleeding propensity before the needle injection occurs, thereby reducing bleeding during the treatment without compromising treatment delivery.
3Reliability
If conventional treatments are used, then treatment effects are achieved, but swelling and inflammation occur
Solution Approach 1:
The patent uses antifibrinolytic agent as an intermediary substance that modulates the treatment area's response to the procedure. By applying tranexamic acid topically, it acts as a mediator that prevents excessive fibrin breakdown and reduces the body's inflammatory response, thereby reducing swelling and inflammation while maintaining treatment efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of antifibrinolytic agents significantly reduces bruising and swelling, extends the duration of dermal fillers and toxins, and accelerates healing, as demonstrated by clinical studies showing a substantial decline in post-treatment adverse reactions and improved treatment efficacy.
Implementation Method 1
applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment... minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment
Data Source
AI summary
In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w/v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.